Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,054 matching trials from the live ClinicalTrials.gov search.
Conditions
Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
Interventions
Pharmacological Study, Romidepsin
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more
Conditions
Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
23
States / cities
Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876, Epacadostat, Pembrolizumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Hackensack, New Jersey
Completed Phase 2 Interventional Results available

Phase IIB TL + YCWP + DC in Melanoma

NCT02301611
Conditions
Melanoma
Interventions
TLPLDC, Placebo
Drug
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more
Conditions
Sentinel Lymph Node, Melanoma (Skin), Breast Cancer
Interventions
IC-Green KIT
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Poughkeepsie, New York • Hershey, Pennsylvania
Completed Phase 2 Interventional Results available

Neoadjuvant and Adjuvant Checkpoint Blockade

NCT02519322
Conditions
Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Relatlimab, Therapeutic Conventional Surgery
Biological · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Hepatocellular Carcinoma
Interventions
propranolol hydrochloride, Correlative Studies
Drug · Other
Lead sponsor
William Carson
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Malignant Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more
Conditions
Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal, Liver Metastases
Interventions
Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed No phase listed Observational Accepts healthy volunteers

Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk

NCT03040492
Conditions
Skin Cancer, Non-Melanoma
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

NCT02743819
Conditions
Melanoma
Interventions
Pembrolizumab, Ipilimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
10
States / cities
Mobile, Alabama • Miami Beach, Florida • Tampa, Florida + 7 more
Conditions
Malignant Melanoma
Interventions
Coxsackievirus A21 (CVA21)
Biological
Lead sponsor
Viralytics
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Miami Beach, Florida + 7 more
Conditions
Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cryosurgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more
Conditions
Uveal Melanoma
Interventions
Selumetinib, 100mg, Selumetinib, 125mg, Selumetinib, 150mg, Selumetinib, 175mg, Selumetinib, 200mg, Selumetinib, 225mg
Drug
Lead sponsor
Shaheer A. Khan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Conditions
Melanoma, Lung Cancer
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Palm Springs, California • Jacksonville, Florida • Lake City, Florida + 9 more
Conditions
Recurrent or Metastatic Solid Tumors
Interventions
Ifinatamab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
Conditions
Stage IV Melanoma
Interventions
Disulfiram (DSF)
Drug
Lead sponsor
John P. Fruehauf
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Orange, California
Conditions
Malignant Melanoma
Interventions
imexon, DTIC
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Conditions
Melanoma
Interventions
Ceralasertib, Durvalumab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
Conditions
Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
Interventions
LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide), Immunotherapy (Pembrolizumab), Immunotherapy (nivolumab and relatlimab), Immunotherapy (ipilimumab and nivolumab)
Biological · Drug
Lead sponsor
Linnaeus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
Newport Beach, California • San Francisco, California • Stanford, California + 6 more
Conditions
Metastatic Melanoma
Interventions
Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
Biological · Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
Conditions
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Interventions
Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Conditions
Metastatic Melanoma
Interventions
E7080
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas